- Previous Close
0.0030 - Open
0.0030 - Bid 0.0030 x --
- Ask 0.0045 x --
- Day's Range
0.0030 - 0.0030 - 52 Week Range
0.0005 - 0.0100 - Volume
293,000 - Avg. Volume
5,203 - Market Cap (intraday)
7.162M - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer's disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient to treat cardiovascular disease, including hypertension. It is also developing AlgaraeOS in partnership with the University of New South Wales, an artificial intelligence platform for biopharmaceutical prediction of both fixed dose combination drug targets and repurposed drug targets agnostic to medical indication. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
algoraepharma.comRecent News: LHI0.F
View MorePerformance Overview: LHI0.F
Trailing total returns as of 12/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LHI0.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LHI0.F
View MoreValuation Measures
Market Cap
8.15M
Enterprise Value
6.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.78
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.67%
Return on Equity (ttm)
-61.85%
Revenue (ttm)
125.2k
Net Income Avi to Common (ttm)
-2.1M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.11M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-482.58k